Hosted by Dr. Neil Love · 🇺🇸 US · EN · 49 episodes
Established thought leaders with verified media credentials.
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
Dr. Neil Love hosts Lung Cancer Update, a science show with 49 episodes published.
Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics: Introduction (0:00) Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (
Featuring an interview with Prof Martin Reck, including the following topics: Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunother
Dr Christine L Hann from the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding
Dr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung cancer and summarize major advances in the treatment landscape reported
Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer. CME information and select publications
Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCL
Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy
Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer. CME information and select publications here.
Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer. CME information and sele
Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publ
Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publi
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publicati
Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for pat
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and s
Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies fo
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as e
Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage t
Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual m
Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical tr
Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches. CME information and select publications here.
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Lung Cancer Update has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Lung Cancer Update is hosted by Dr. Neil Love. The show is categorised under science (health) and has published 49 episodes.
Lung Cancer Update has published 49 episodes.
Lung Cancer Update regularly covers science, health, fitness. It sits in the science category, with a health focus.
Lung Cancer Update is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Lung Cancer Update hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Lung Cancer Update average 56 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Lung Cancer Update's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 2 days ago.
